Cargando…

Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients

BACKGROUND: Lipoprotein apheresis (LA) is considered as an add-on therapy for patients with familial hypercholesterolemia (FH). We aimed to analyze the data collected in the last 15 years from FH patients treated with LA, to elucidate the benefit of this procedure with respect to plasma lipids, biom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Víšek, J., Bláha, M., Bláha, V., Lášticová, M., Lánska, M., Andrýs, C., Tebbens, J. Duintjer, Igreja e Sá, Ivone Cristina, Tripská, K., Vicen, M., Najmanová, I., Nachtigal, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913462/ https://www.ncbi.nlm.nih.gov/pubmed/33640001 http://dx.doi.org/10.1186/s13023-021-01749-w

Ejemplares similares

Long term effects of soluble endoglin and mild hypercholesterolemia in mice hearts
por: Vitverova, Barbora, et al.
Publicado: (2020)

Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells
por: Tripska, Katarina, et al.
Publicado: (2022)

High Soluble Endoglin Levels Affect Aortic Vascular Function during Mice Aging
por: Nejmanová, Iveta, et al.
Publicado: (2021)

Labetalol and soluble endoglin aggravate bile acid retention in mice with ethinylestradiol-induced cholestasis
por: Cristina Igreja Sá, Ivone, et al.
Publicado: (2023)

Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver
por: Igreja Sá, Ivone Cristina, et al.
Publicado: (2020)

Long-Term LDL-Apheresis Treatment and Dynamics of Circulating miRNAs in Patients with Severe Familial Hypercholesterolemia
por: Dlouha, Dana, et al.
Publicado: (2023)

Multiplex Protein Biomarker Profiling in Patients with Familial Hypercholesterolemia
por: Dlouha, Dana, et al.
Publicado: (2021)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia
por: Connolly, Katherine D., et al.
Publicado: (2014)

Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years
por: Filip, Stanislav, et al.
Publicado: (2020)

Erratum: Filip, S.; et al. Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years. Pharmaceutics 2020, 12, 940
por: Filip, Stanislav, et al.
Publicado: (2020)

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection
por: Julius, Ulrich
Publicado: (2016)

Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis
por: Fahed, Akl C., et al.
Publicado: (2012)

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
por: Wang, Anthony, et al.
Publicado: (2016)

Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia
por: Wen, Jun, et al.
Publicado: (2019)

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis center
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

An update on lipid apheresis for familial hypercholesterolemia
por: Taylan, Christina, et al.
Publicado: (2022)

High Soluble Endoglin Levels Do Not Induce Endothelial Dysfunction in Mouse Aorta
por: Nemeckova, Ivana, et al.
Publicado: (2015)

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia
por: Puntoni, Mariarita, et al.
Publicado: (2011)

Usefulness of Lipid Apheresis in the Treatment of Familial Hypercholesterolemia
por: Lui, Matthew, et al.
Publicado: (2014)

Successful Direct Adsorption of Lipoproteins (DALI) Apheresis During Pregnancy in an Omani Woman with Homozygous Familial Hypercholesterolemia
por: Al-Dughaishi, Tamima, et al.
Publicado: (2015)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease
por: Heigl, Franz, et al.
Publicado: (2015)

MMP-15 Is Upregulated in Preeclampsia, but Does Not Cleave Endoglin to Produce Soluble Endoglin
por: Kaitu’u-Lino, Tu’uhevaha J., et al.
Publicado: (2012)

Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab
por: Tanaka, Akihito, et al.
Publicado: (2017)

Role of soluble endoglin in BMP9 signaling
por: Lawera, Aleksandra, et al.
Publicado: (2019)

The effect of DALI lipid apheresis in the prognosis of homozygous familial hypercholesterolemia: Seven patients' experience at a DALI apheresis center
por: Bulut, Muhammet, et al.
Publicado: (2020)

MMP-12, Secreted by Pro-Inflammatory Macrophages, Targets Endoglin in Human Macrophages and Endothelial Cells
por: Aristorena, Mikel, et al.
Publicado: (2019)

Extracorporeal Immunoglobulin Elimination for the Treatment of Severe Myasthenia Gravis
por: Blaha, M., et al.
Publicado: (2010)

HELP LDL Apheresis Reduces Plasma Pentraxin 3 in Familial Hypercholesterolemia
por: Zanetti, Michela, et al.
Publicado: (2014)

Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia
por: Varga, Viktória E., et al.
Publicado: (2016)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
por: Greco, Maria Francesca, et al.
Publicado: (2020)

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Use of Ultra High Performance Liquid Chromatography-Tandem Mass Spectrometry to Demonstrate Decreased Serum Statin Levels after Extracorporeal LDL-Cholesterol Elimination
por: Bláha, M., et al.
Publicado: (2011)

Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis
por: Weylandt, Karsten-H., et al.
Publicado: (2019)

Lipoprotein apheresis efficacy and challenges: single center experience
por: Özdemir, Zehra Narlı, et al.
Publicado: (2022)

Low-density lipoprotein apheresis in a pediatric patient of familial hypercholesterolemia: Primi experientia from a tertiary care center in North India
por: Dogra, Kanchan, et al.
Publicado: (2017)

Just not cosmesis! Role of low-density lipoprotein apheresis in familial hypercholesterolemia: Experience at a newly developed tertiary care institution in Northern India
por: Kaur, Daljit, et al.
Publicado: (2021)

The Impact of Lipoprotein Apheresis on Oxidative Stress Biomarkers and High-Density Lipoprotein Subfractions
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ch0ldpsf70uv8auqf9q0dh41jv